Top

Published in:

01-04-2019 | Original Scientific Report

Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for “Borderline Resectable” in the Field of Surgery for Hilar Cholangiocarcinoma

Authors: Ryusei Matsuyama, Daisuke Morioka, Ryutaro Mori, Yasuhiro Yabushita, Seigo Hiratani, Yohei Ota, Takafumi Kumamoto, Itaru Endo

Published in: World Journal of Surgery | Issue 4/2019

Abstract

Background

The concept of “borderline resectable” was recently introduced to the field of surgery for pancreatic cancer, and surgical outcomes for this disease with extremely dismal prognosis have improved since the introduction of this concept. However, no such concept has yet been introduced to the field of surgery for hilar cholangiocarcinoma (HCca).

Aim

To determine a definition and criteria for “borderline resectable” in the field of surgery for HCca.

Patients and methods

Retrospective analysis of 88 patients undergoing curative-intent surgery for HCca at our institution between May 1992 and December 2008 to clarify independent prognostic factors.

Results

Survival outcomes were obtained for these 88 patients, with a 5-year overall survival rate of 31.8%. Independent factors predictive of cancer death were determined by multivariate analysis to be the presence of regional lymph node metastasis (LNM) and pathological confirmed vascular invasion (VI). Cumulative survival rates of 23 patients with both LNM and VI who underwent surgery were significantly worse than those of the remaining 65 surgically treated patients and similar to those of 26 patients who were considered to have unresectable disease and treated with non-surgical multidisciplinary treatment during the same study period.

Conclusion

Outcomes of surgery for cases of HCca showing regional LNM and VI were no better than those of non-surgical treatment for unresectable disease. Coexistence of these two factors indicates oncologically dismal condition and thus such cases should be considered “borderline resectable.” Treatments additional to surgery are required for “borderline resectable” cases to obtain better outcomes.

Ito F, Cho CS, Rikkers LF et al (2009) Hilar cholangiocarcinoma: current management. Ann Surg 250:210–218CrossRefPubMed

Nagino M (2012) Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topics. J Gastroenterol 47:1165–1176CrossRefPubMed

Poruk KE, Pawlik TM, Weiss MJ (2015) Perioperative management of Hilar cholangiocarcinoma. J Gastrointest Surg 19:1889–1899CrossRefPubMedPubMedCentral

Verbeek PC, van Leeuwen DJ, de Wit LT et al (1992) Benign fibrosing disease at the hepatic confluence mimicking Klatskin tumors. Surgery 112:866–871PubMed

Baer HU, Stain SC, Dennison AR et al (1993) Improvements in survival by aggressive resections of hilar cholangiocarcinoma. Ann Surg 217:20–27CrossRefPubMedPubMedCentral

Miyazaki M, Kato A, Ito H et al (2007) Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it works or not? Surgery 141:581–588CrossRefPubMed

Hemming AW, Makeel K, Khanna A et al (2011) Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg 212:604–613CrossRefPubMed

Neuhaus P, Thelen A, Jonas S et al (2012) Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol 19:1602–1608CrossRefPubMed

de Jong MC, Marques H, Clary BM et al (2012) The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 118:4737–4747CrossRefPubMed

10.

Tamoto E, Hirano S, Tsuchikawa T et al (2014) Portal vein resection using the no-touch technique with a hepatectomy for hilar cholangiocarcinoma. HPB (Oxford) 16:56–61CrossRef

11.

Wu XS, Dong P, Gu J et al (2013) Combined portal vein resection for hilar cholangiocarcinoma: a metaanalysis of comparative studies. J Gastrointes Surg 17:1107–1115CrossRef

12.

Abbas S, Sandroussi C (2013) Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford) 15:492–503CrossRef

13.

Chen W, Ke K, Chen YL (2014) Combined portal vein resection in the treatment of hilar cholangiocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol 40:489–495CrossRefPubMed

14.

Igami T, Nishio T, Ebata T et al (2010) Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya experience. J Hepatobiliary Pancreat Surg 17:449–454CrossRef

15.

Miyazaki M, Kimura F, Shimizu H et al (2010) One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci 17:470–475CrossRefPubMed

16.

Nuzzo G, Giuliante F, Ardito F et al (2012) Improvements in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 147:26–34CrossRefPubMed

17.

Matsuo K, Rocha FG, Ito K et al (2012) The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 215:343–355CrossRefPubMed

18.

Ratti F, Cipriani F, Piozzi G et al (2015) Comparative analysis of left- versus right-sided resection in Klatskin tumor surgery: can lesion side be considered a prognostic factor? J Gastrointest Surg 19:1324–1333CrossRefPubMed

19.

Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846CrossRefPubMedPubMedCentral

20.

Ferrone CR, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17CrossRefPubMedPubMedCentral

21.

Khushman M, Dempsey N, Cudris Maldonado J et al (2015) Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology 15:667–673CrossRefPubMed

22.

National Comprehensive Cancer Network Guideline for Pancreatic Adenocarcinoma. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

23.

Choi ER, Chung YH, Lee JK et al (2011) Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography. J Gastroenterol Hepatol 26:1803–1810. https://doi.org/10.1111/j.1440-1746.2011.06804.x CrossRef

24.

Wakai T, Shirai Y, Moroda T et al (2015) Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 103:1210–1216CrossRef

25.

Koo TR, Eom KY, Kim IA et al (2014) Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy. Raidat Oncol J 32:63–69. https://doi.org/10.3857/roj.2014.32.2.63 CrossRef

26.

Im JH, Seong J, Lee J et al (2014) Postoperative radiotherapy dose correlates with locoregional control in patients with extra-hepatic bile duct cancer. Radiat Oncol J 32:7–13. https://doi.org/10.3857/roj.2014.32.1.7 CrossRefPubMedPubMedCentral

27.

Bismuth H, Corlette MBm (1975) Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 140:170–178PubMed

28.

International Union Against Cancer (UICC) (2009) TNM classification of malignant tumors, 7th edn. Wiley-Liss, New York

29.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral

30.

Neuhaus P, Jonas S, Bechstein WO et al (1999) Extended resections for hilar cholangiocarcinoma. Ann Surg 230:808–818CrossRefPubMedPubMedCentral

31.

Nimura Y, Kamiya J, Kondo S et al (2000) Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 7:155–162CrossRefPubMed

32.

Rea DJ, Munoz-Juarez M, Farnell MB et al (2004) Major hepatic resection for hilar choangiocarcinoma: analysis of 46 patients. Arch Surg 139:514–523CrossRefPubMed

33.

Witzigmann H, Berr F, Ringel U et al (2006) Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy is comparable to r1/r2 resection. Ann Surg 244:230–239CrossRefPubMedPubMedCentral

34.

Baton O, Azoulay D, Adam DV et al (2007) Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and long-term outcomes. J Am Coll Surg 204:250–260CrossRefPubMed

35.

Gomez D, Patel PB, Lacasia-Purroy C et al (2014) Impact of specialized multi-disciplinary approach and an integrated pathway on outcomes in hilar cholangiocarcinoma. Eur J Surg Oncol 40:77–84CrossRefPubMed

36.

Furusawa N, Kobayashi A, Yokoyama T et al (2014) Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality. World J Surg 38:1164–1176. https://doi.org/10.1007/s00268-013-2394-x CrossRefPubMed

37.

Hosokawa I, Shimizu H, Yoshidome H et al (2014) Surgical strategy for hilar cholangiocarcinoma of the left-side predominance: current role of left trisectionectomy. Ann Surg 259:1178–1185CrossRefPubMed

38.

Murakami Y, Uemura K, Sudo T et al (2009) Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 13:1470–1479. https://doi.org/10.1007/s11605-009-0900-0 CrossRefPubMed

39.

Murakami Y, Uemura K, Sudo T et al (2009) Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250:950–956. https://doi.org/10.1097/SLA.0b013e3181b0fc8b CrossRefPubMed

40.

Fujiwara Y, Kobayashi S, Nagano H et al (2015) Pharmacokinetic study of adjuvant gemcitabine therapy for biliary tract cancer following major hepatectomy (KHB01101). PLoS ONE 10:e0143072. https://doi.org/10.1371/journal.pone.0143072 CrossRefPubMedPubMedCentral

41.

Endo I, Shimada H, Sugita M et al (2007) Role of three-dimensional imaging in operative planning for hilar cholangiocarcinoma. Surgery 142:666–675CrossRefPubMed

42.

Hu JH, Tang JH, Lin CH et al (2018) Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis. J Investig Med 66:52–61. https://doi.org/10.1136/jim-2017-000472 CrossRefPubMed

43.

Ma KW, Cheung TT, She WH et al (2018) Diagnostic and prognostic role of 18-FDG PET/CT in the management of resectable biliary tract cancer. World J Surg 42:823–834. https://doi.org/10.1007/s00268-017-4192-3 CrossRefPubMed

44.

Morine Y, Shimada M, Imura S et al (2015) Detection of lymph node metastasis in biliary carcinomas: morphological criteria by MDCT and the clinical impact of DWI-MRI. Hepatogastroenterology 62:777–781PubMed

45.

Holzapfel K, Gaa J, Schubert EC et al (2016) Value of diffusion-weighed MR imaging in the diagnosis of lymph node metastases in patients with cholangiocarcinoma. Abdom Radiol (NY) 41:1937–1941. https://doi.org/10.1007/s00261-016-0791-y CrossRef

46.

Yamashita S, Passot G, Aloia TA et al (2017) Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg 104:267–277. https://doi.org/10.1002/bjs.10415 CrossRefPubMed

47.

Matsuyama R, Morioka D, Mori R et al (2018) Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study. Cancer Chemother Pharmacol 81:949–955. https://doi.org/10.1007/s00280-018-3566-z CrossRefPubMed

Title: Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for “Borderline Resectable” in the Field of Surgery for Hilar Cholangiocarcinoma
Authors: Ryusei Matsuyama
Daisuke Morioka
Ryutaro Mori
Yasuhiro Yabushita
Seigo Hiratani
Yohei Ota
Takafumi Kumamoto
Itaru Endo
Publication date: 01-04-2019
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 4/2019
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-018-04883-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for “Borderline Resectable” in the Field of Surgery for Hilar Cholangiocarcinoma

Abstract

Background

Aim

Patients and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Aim

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2019

The Evolving Role of Vacuum Assisted Biopsy of the Breast: A Progression from Fine-Needle Aspiration Biopsy

Stent-Assisted Percutaneous Endoscopic Necrosectomy for Infected Pancreatic Necrosis: Technical Report and a Pilot Study

Robotic Versus Conventional Laparoscopic Surgery for Colorectal Cancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis

Controlling Nutritional Status (CONUT) Score Predicts Outcomes of Curative Resection for Gastric Cancer in the Elderly

Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma

Optimal Resources for Children’s Surgical Care: Executive Summary